Performance of treatment response scoring systems among patients with multiple sclerosis treated with high-efficacy therapies.

IF 5 2区医学 Q1 CLINICAL NEUROLOGY

Multiple Sclerosis Journal Pub Date : 2025-04-01 Epub Date: 2025-02-10 DOI:10.1177/13524585251316471

Mariano Marrodan, Augusto Sao Avilés, Jordi Río, Álvaro Cobo-Calvo, Victoria Fernández, Agustin Pappolla, Joaquín Castilló, Ángela Vidal-Jordana, Georgina Arrambide, Carmen Tur, Breogán Rodríguez-Acevedo, Ana Zabalza, Neus Mongay-Ochoa, Andreu Vilaseca, Marta Rodriguez, Ingrid Galán, Manuel Comabella, Jaume Sastre-Garriga, Mar Tintoré, Cristina Auger, Àlex Rovira, Xavier Montalban, Luciana Midaglia

{"title":"Performance of treatment response scoring systems among patients with multiple sclerosis treated with high-efficacy therapies.","authors":"Mariano Marrodan, Augusto Sao Avilés, Jordi Río, Álvaro Cobo-Calvo, Victoria Fernández, Agustin Pappolla, Joaquín Castilló, Ángela Vidal-Jordana, Georgina Arrambide, Carmen Tur, Breogán Rodríguez-Acevedo, Ana Zabalza, Neus Mongay-Ochoa, Andreu Vilaseca, Marta Rodriguez, Ingrid Galán, Manuel Comabella, Jaume Sastre-Garriga, Mar Tintoré, Cristina Auger, Àlex Rovira, Xavier Montalban, Luciana Midaglia","doi":"10.1177/13524585251316471","DOIUrl":null,"url":null,"abstract":"Background: Predicting treatment response and disease progression in multiple sclerosis (MS) is challenging. Treatment Response Scoring Systems (TRSS) are potentially useful, but their utility in patients receiving high-efficacy therapies and very high-efficacy therapies (HET/vHET) remains unclear.Objective: This study aimed to evaluate the performance of TRSS in patients treated with HET/vHET.Methods: We retrospectively studied MS patients treated with HET/vHET in an MS specialized centre. TRSS, including the Rio Score, modified Rio Score and MAGNIMS score, were applied to assess response to treatment. We evaluated the predictive value of the TRSS on disease activity and disability progression.Results: TRSS effectively predicted disease activity and progression of disability in patients treated with HET/vHET. Patients with high TRSS scores at 12 months post-HET/vHET initiation had a significantly increased risk of relapses, new lesions on magnetic resonance imaging (MRI) scans and progression of disability at 4 years.Discussion: Our findings highlight the importance of personalized treatment strategies in MS. TRSS are valuable tools for monitoring treatment response, guiding clinical decision-making and optimizing patient care.","PeriodicalId":18874,"journal":{"name":"Multiple Sclerosis Journal","volume":" ","pages":"568-577"},"PeriodicalIF":5.0000,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Multiple Sclerosis Journal","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/13524585251316471","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/2/10 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Predicting treatment response and disease progression in multiple sclerosis (MS) is challenging. Treatment Response Scoring Systems (TRSS) are potentially useful, but their utility in patients receiving high-efficacy therapies and very high-efficacy therapies (HET/vHET) remains unclear.

Objective: This study aimed to evaluate the performance of TRSS in patients treated with HET/vHET.

Methods: We retrospectively studied MS patients treated with HET/vHET in an MS specialized centre. TRSS, including the Rio Score, modified Rio Score and MAGNIMS score, were applied to assess response to treatment. We evaluated the predictive value of the TRSS on disease activity and disability progression.

Results: TRSS effectively predicted disease activity and progression of disability in patients treated with HET/vHET. Patients with high TRSS scores at 12 months post-HET/vHET initiation had a significantly increased risk of relapses, new lesions on magnetic resonance imaging (MRI) scans and progression of disability at 4 years.

Discussion: Our findings highlight the importance of personalized treatment strategies in MS. TRSS are valuable tools for monitoring treatment response, guiding clinical decision-making and optimizing patient care.

查看原文本刊更多论文

治疗反应评分系统在接受高效治疗的多发性硬化症患者中的表现

背景：预测多发性硬化症（MS）的治疗反应和疾病进展具有挑战性。治疗反应评分系统（TRSS）可能有用，但其在接受高效治疗和非常高效治疗（HET/vHET）的患者中的效用尚不清楚。目的：本研究旨在评价TRSS在HET/vHET治疗患者中的表现。方法：我们回顾性研究在多发性硬化症专科中心接受HET/vHET治疗的多发性硬化症患者。TRSS包括里约热内卢评分、改良里约热内卢评分和MAGNIMS评分，用于评估治疗反应。我们评估了TRSS对疾病活动性和残疾进展的预测价值。结果：TRSS有效预测了HET/vHET治疗患者的疾病活动性和残疾进展。在het /vHET开始后12个月TRSS评分高的患者复发、磁共振成像（MRI）扫描新病变和4年残疾进展的风险显著增加。讨论：我们的研究结果强调了个性化治疗策略在ms中的重要性，TRSS是监测治疗反应、指导临床决策和优化患者护理的宝贵工具。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Multiple Sclerosis Journal 医学-临床神经学

CiteScore

10.90

自引率

6.90%

发文量

186

审稿时长

3-8 weeks

期刊介绍： Multiple Sclerosis Journal is a peer-reviewed international journal that focuses on all aspects of multiple sclerosis, neuromyelitis optica and other related autoimmune diseases of the central nervous system. The journal for your research in the following areas: * __Biologic basis:__ pathology, myelin biology, pathophysiology of the blood/brain barrier, axo-glial pathobiology, remyelination, virology and microbiome, immunology, proteomics * __Epidemology and genetics:__ genetics epigenetics, epidemiology * __Clinical and Neuroimaging:__ clinical neurology, biomarkers, neuroimaging and clinical outcome measures * __Therapeutics and rehabilitation:__ therapeutics, rehabilitation, psychology, neuroplasticity, neuroprotection, and systematic management Print ISSN: 1352-4585